Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry

Seminars in Arthritis and Rheumatism

Volumn 45, Issue 3, 2015, Pages 309-314

  Hinchcliff, Monique ^a   Khanna, Saira ^b   Hsu, Vivien M ^c   Lee, Jungwha ^a   Almagor, Orit ^a   Chang, Rowland W ^a   Steen, Virginia ^d   Chung, Lorinda ^e   Bolster, Marcy B ^f   Csuka, Mary E ^g   Derk, Chris T ^h   Domsic, Robyn T ⁱ   Fischer, Aryeh ^j   Frech, Tracy ^k   Furst, Daniel ^l   Goldberg, Avram Z ^m,x,y   Gomberg Maitland, Mardi ^n,z   Gordon, Jessica K ^o   Hummers, Laura K ^p   Kassab, Firas ^q,aa   Molitor, Jerry A ^r   Preston, Ioana ^s   Ann Saketkoo, Lesley ^t   Schiopu, Elena ^u   Silver, Rick ^v   Simms, Robert ^w   Varga, John ^x   more..

^a NORTHWESTERN UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e STANFORD UNIVERSITY   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF COLORADO   (United States)

^k UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m Northwell Health   (United States)

ⁿ UNIVERSITY OF CHICAGO   (United States)

^o HOSPITAL FOR SPECIAL SURGERY   (United States)

^p JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^r UNIVERSITY OF MICHIGAN   (United States)

^s UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^t TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^u TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^v MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^w BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^x NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^y Rheumatology Associates   (United States)

^z UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^aa UNIVERSITY OF NORTH CAROLINA   (United States)

more..

Author keywords

Mortality; Pulmonary arterial hypertension; Pulmonary hypertension; Risk factors; Scleroderma; Serum autoantibody; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CENTROMERE ANTIBODY; RNA POLYMERASE III ANTIBODY; SCL 70 ANTIBODY; U3 RIBONUCLEOPROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE REGISTRY; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL RATE; SYSTEMIC SCLEROSIS; AGED; BLOOD; COMPLICATION; IMMUNOLOGY; MIDDLE AGED; PROGNOSIS; REGISTER;

ADULT; AGED; AUTOANTIBODIES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROGNOSIS; REGISTRIES; SCLERODERMA, SYSTEMIC;

EID: 84955693022     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2015.06.011     Document Type: Article

References (12)

1. Nihtyanova S.I., Schreiber B.E., Ong V.H., Rosenberg D., Moinzadeh P., Coghlan J.G., et al. Prediction of pulmonary complications and long term survival in systemic sclerosis. Arthritis Rheumatol (Hoboken, NJ) 2014, 66:1625-1635.
2. Chung L., Liu J., Parsons L., Hassoun P.M., McGoon M., Badesch D.B., et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010, 138:1383-1394.
3. Steen V.D. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35:35-42.
4. Doering K., Rosen A. Autoantibodies in pathogenesis. Scleroderma: from pathogenesis to comprehensive management 2012, 199-208. Springer, New York, Dordrecht, Heidelberg, London. J. Varga, C. Denton, F. Wigley (Eds.).
5. Galie N., Hoeper M.M., Humbert M., Torbicki A., Vachiery J.L., Barbera J.A., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009, 34:1219-1263.
6. Hinchcliff M., Fischer A., Schiopu E., Steen V.D., PHAROS Investigators Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol 2011, 38:2172-2179.
7. Steen V., Medsger T.A. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003, 48:516-522.
8. Chung L., Domsic R.T., Lingala B., Alkassab F., Bolster M., Csuka M.E., et al. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken) 2014, 66:489-495.
9. Yaqub A., Chung L. Epidemiology and risk factors for pulmonary hypertension in systemic sclerosis. Curr Rheumatol Rep 2013, 15:302.
10. Nikpour M., Baron M. Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. Curr Opin Rheumatol 2014, 26:131-137.
11. Chung L., Farber H.W., Benza R., Miller D.P., Parsons L., Hassoun P.M., et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest 2014, 146:1494-1504.
12. Williams M.H., Handler C.E., Akram R., Smith C.J., Das C., Smee J., et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006, 27:1485-1494.